Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
α-Glucosidase inhibitors (AGIs) have been reported for their clinical potential against postprandial hyperglycemia, which is responsible for the risks associated with diabetes mellitus 2 and cardiovascular diseases (CVDs).
|
28745232 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitory action of F. halophila extracts (acetone, chloroform, and methanol) against key enzymes linked to diabetes (α-amylase, α-glucosidase), cognitive functions (acetyl cholinesterase (AChE), butyryl cholinesterase (BChE)), and hyperpigmentation (tyrosinase) was assessed.
|
30121555 |
2018 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The animal experiments showed that diabetes increased intestinal disaccharidase activities, accompanied by high mRNA and protein expression of SI complex.
|
21946084 |
2011 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The results demonstrate that ultrafiltration with liquid chromatography and mass spectrometry combined with high-speed counter-current chromatography is not only a powerful tool for screening and isolating α-glucosidase and lactate dehydrogenase inhibitors in complex samples, but also a useful platform for identifying bioactive compounds for preventing and treating diabetes and stroke.
|
30444083 |
2018 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Chalcones, originated from natural product, have been broadly studied their biological activity against various proteins which at the molecular level, are responsible for the progress of the diseases in cancer (e.g. kinases), inflammation (oxidoreductases), atherosclerosis (cathepsins receptor), and diabetes (e.g.α-glucosidase).
|
31808389 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase are important targets to treat obesity and diabetes, due to their deep correlation with insulin and leptin signalling, and glucose regulation.
|
28933230 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The findings of this work supported that N. oleracea is a rich source of phenolics that can be potential antioxidants and α-glucosidase inhibitors for the management of diabetes.
|
30616569 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Peptide-based therapeutics offer a unique avenue for the development of novel agents for the treatment of diabetes mellitus including α-glucosidase inhibitors.
|
30919765 |
2019 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Accordingly, nutritional composition, the content of phytochemical antioxidants, and the inhibitory ability of key enzymes with impacts on obesity and diabetes (α-glucosidase and pancreatic lipase) or on arterial pressure (angiotensin-I converting enzyme), were evaluated.
|
30274353 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Voglibose and acarbose are distinguished α-glucosidase inhibitors used for controlling of diabetes mellitus.
|
31699396 |
2020 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased α-glucosidase, PEPCK, GLUT-2 and SGLTs levels with the induction of diabetes considerably lowered with TPSE treatment.
|
30399410 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Since hypoglycemia can occur in diabetes disease and there is a significant link between diabetes and cardiovascular diseases (CVD), thus this study aimed to evaluate the inhibitory properties of DP against α-Amy and α-Glu, as enzyme targets of interest under hypoglycemia condition.
|
31078769 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Lxn significantly inhibited (p < 0.05) the activity of α-amylase and α-glucosidase and could be of medical and nutritional relevance in the treatment of diabetes.
|
28170007 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We performed a systematic review and meta-analysis to evaluate the effect of alpha-glucosidase inhibitors (AGIs) on the risk of cancer in patients with diabetes mellitus.
|
29113364 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-α-glucosidase (AAG) compounds have received great attention due to their potential use in treating diabetes.
|
30769933 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum catalase and insulin levels, body weight and blood glucose levels (BGL), alpha-glucosidase inhibition, lipid peroxidation and glycated hemoglobin (HbA1c) were measured to evaluate both alloxan-induced diabetes mellitus and diabetic painful neuropathy (DPN).
|
29234979 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibitory potential against key enzymes involved in diabetes (α-glucosidase and α-amylase), obesity (pancreatic lipase), neurodegenerative diseases (cholinesterases), and hyperpigmentation (tyrosinase) was evaluated.
|
28040595 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken altogether, in vitro and in vivo experiments suggest that selected natural compounds (curcumin, antroquinonol, HCD, docosanol, tetracosanol, rutin, and actinodaphnine) via molecular docking were confirmed as potential candidates of α-glucosidase and α-amylase inhibitors for treating diabetes.
|
30189596 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
As the close correlation between α-glucosidase inhibitors and the treatment of diabetes, in combination with capillary electrophoresis (CE), a method was developed to screen α-glucosidase inhibitors from traditional Chinese medicines (TCMs) by immobilizing α-glucosidase on magnetic nanoparticles.
|
28107971 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
α-Glucosidase inhibitors have been approved as therapeutic agents for diabetes.
|
31555798 |
2019 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
EAE was the most effective enzyme inhibitor, exhibiting the highest inhibition against some enzymes linked to Alzheimer's disease (cholinesterases), diabetes mellitus (α-glucosidase and α-amylase) and hyperpigmentation problems (tyrosinase).
|
30466026 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Gray, and <i>Salvia officinalis</i> L. decoctions were investigated for their health-benefit properties, in particular with respect to antioxidant activity and inhibitory ability towards key enzymes with impact in diabetes and obesity (α-glucosidase, α-amylase and pancreatic lipase).
|
30513773 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Mulberry 1-deoxynojirimycin (DNJ), an inhibitor of α-glucosidase, has been reported to help prevent diabetes mellitus and suppress lipid accumulation.
|
24050301 |
2013 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The inhibition of α-glucosidase, a key carbohydrate hydrolyzing enzyme, could serve as one of the effective methodology in both preventing and treating diabetes through controlling the postprandial glucose levels and suppressing postprandial hyperglycemia.
|
29421697 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
α-Glucosidase and its inhibitors play a key role in diagnosis and treatment of diabetes.
|
31670357 |
2019 |